RBC Capital Reiterates Outperform on IDEAYA Biosciences, Maintains $61 Price Target
Portfolio Pulse from Benzinga Newsdesk
RBC Capital has reiterated its 'Outperform' rating for IDEAYA Biosciences, maintaining a price target of $61. This suggests confidence in the company's future performance.
September 24, 2024 | 12:41 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
RBC Capital has reiterated its 'Outperform' rating for IDEAYA Biosciences, maintaining a price target of $61. This suggests confidence in the company's future performance.
The reiteration of an 'Outperform' rating and a maintained price target of $61 by RBC Capital indicates strong confidence in IDEAYA Biosciences' future performance. Such analyst ratings can positively influence investor sentiment and potentially lead to a short-term increase in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100